(Q412323)

English

rituximab

pharmaceutical drug

IDEC-102
RG-105
IDEC-C2B8
AntiCD20
R-105 IDEC-102
Ig gamma-1 chain C region
Rituxan
Mabthera

In more languages

default for all languages

No label defined

No description defined

Statements

type of chemical entity

0 references

chemical compound

0 references

1 reference

Rituximab (English)

language of work or name

publication date

17 November 2015

image of molecular model or crystal lattice model

Rituximab.png
1,020 × 625; 262 KB

0 references

active ingredient in

1 reference

European Medicines Agency product number

EMEA/H/C/000165

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000165/human_med_000897.jsp

22 March 2017

medical condition treated

B-cell lymphoma

2 references

language of work or name

13 December 2016

Drug Indications Extracted from FAERS

2 October 2018

hairy cell leukemia

1 reference

Drug Indications Extracted from FAERS

2 October 2018

granulomatosis with polyangiitis

1 reference

Drug Indications Extracted from FAERS

2 October 2018

chronic lymphocytic leukemia

1 reference

Drug Indications Extracted from FAERS

2 October 2018

nephrotic syndrome

1 reference

Drug Indications Extracted from FAERS

2 October 2018

1 reference

Drug Indications Extracted from FAERS

2 October 2018

post-transplant lymphoproliferative disorder

1 reference

Drug Indications Extracted from FAERS

2 October 2018

1 reference

Drug Indications Extracted from FAERS

2 October 2018

diffuse large B-cell lymphoma

1 reference

Drug Indications Extracted from FAERS

2 October 2018

lupus nephritis

1 reference

Drug Indications Extracted from FAERS

2 October 2018

1 reference

Drug Indications Extracted from FAERS

2 October 2018

interstitial lung disease

1 reference

Drug Indications Extracted from FAERS

2 October 2018

Waldenström macroglobulinemia

1 reference

Drug Indications Extracted from FAERS

2 October 2018

thrombotic thrombocytopenic purpura

1 reference

Drug Indications Extracted from FAERS

2 October 2018

graft-versus-host disease

1 reference

Drug Indications Extracted from FAERS

2 October 2018

microscopic polyangiitis

1 reference

Drug Indications Extracted from FAERS

2 October 2018

cryoglobulinemia

1 reference

Drug Indications Extracted from FAERS

2 October 2018

non-Hodgkin lymphoma

1 reference

Drug Indications Extracted from FAERS

2 October 2018

myasthenia gravis

1 reference

Drug Indications Extracted from FAERS

2 October 2018

neuromyelitis optica

1 reference

Drug Indications Extracted from FAERS

2 October 2018

1 reference

Drug Indications Extracted from FAERS

2 October 2018

thrombocytopenia

1 reference

Drug Indications Extracted from FAERS

2 October 2018

Sjögren's syndrome

1 reference

Drug Indications Extracted from FAERS

2 October 2018

membranous glomerulonephritis

1 reference

Drug Indications Extracted from FAERS

2 October 2018

central nervous system lymphoma

1 reference

Drug Indications Extracted from FAERS

2 October 2018

mantle cell lymphoma

1 reference

Drug Indications Extracted from FAERS

2 October 2018

autoimmune hemolytic anemia

1 reference

Drug Indications Extracted from FAERS

2 October 2018

bullous pemphigoid

1 reference

Drug Indications Extracted from FAERS

2 October 2018

multiple sclerosis

1 reference

Drug Indications Extracted from FAERS

2 October 2018

Castleman's disease

1 reference

Drug Indications Extracted from FAERS

2 October 2018

AntiMOG associated encephalomyelitis

0 references

legal status (medicine)

1 reference

https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/343802

FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links. (English)

pregnancy category

US pregnancy category C

1 reference

imported from Wikimedia project

English Wikipedia

LiverTox likelihood score

LiverTox toxicity likelihood category A

1 reference

8 April 2021

https://www.ncbi.nlm.nih.gov/books/n/livertox/Rituximab

18 June 2018

1 reference

https://www.pfizer.com/products/product-list

has characteristic

biopharmaceutical

1 reference

Rituximab (English)

language of work or name

publication date

17 November 2015

subject has role

immunologic factor

1 reference

Medical Subject Headings

MeSH descriptor ID

15 March 2018

disease-modifying antirheumatic drug

1 reference

Medical Subject Headings

MeSH descriptor ID

15 March 2018

immunological antineoplastic agent

1 reference

Medical Subject Headings

MeSH descriptor ID

15 March 2018

essential medicine

0 references

monoclonal antibody

1 reference

language of work or name

Rituximab (English)

publication date

17 November 2015

riTUXimab

has characteristic

Tall Man lettering

Institute for Safe Medication Practices

1 reference

https://www.ismp.org/recommendations/tall-man-letters-list

2 September 2022

0 references

Commons category

Rituximab

0 references

Identifiers

987007554340605171

1 reference

National Library of Israel Names and Subjects Authority File

subject named as

rituximab

0 references

CAS Registry Number

2 references

Rituximab (English)

publication date

17 November 2015

Rituximab (English)

24 April 2016

http://chem.sis.nlm.nih.gov/chemidplus/rn/174722-31-7

1 reference

language of work or name

Rituximab (English)

19 January 2016

1 reference

Hazardous Substances Data Bank

publication date

28 October 2019

RITUXIMAB (English)

10 May 2021

DSSTox substance ID

0 references

0 references

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

27 December 2018

Immunoglobulin G1, anti-(human CD20 (antigen)) (human-mouse monoclonal IDEC-C2B8 .gamma.1-chain), disulfide with human-mouse monoclonal IDEC-C2B8 .kappa.-chain, dimer (English)

CAS no.: 174722-31-7 (English)

ECHA Substance Infocard ID

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

27 December 2018

Immunoglobulin G1, anti-(human CD20 (antigen)) (human-mouse monoclonal IDEC-C2B8 .gamma.1-chain), disulfide with human-mouse monoclonal IDEC-C2B8 .kappa.-chain, dimer (English)

CAS no.: 174722-31-7 (English)

1 reference

language of work or name

Rituximab (English)

publication date

17 November 2015

Guide to Pharmacology Ligand ID

0 references

MeSH descriptor ID

subject named as

Rituximab

0 references

D12.776.124.486.485.114.224.075.785

0 references

D12.776.124.790.651.114.224.075.785

0 references

D12.776.377.715.548.114.224.284.785

0 references

1 reference

26 February 2018

0 references

2 references

RITUXIMAB (English)

19 January 2016

Rituximab (English)

24 April 2016

http://chem.sis.nlm.nih.gov/chemidplus/rn/174722-31-7

MedlinePlus drug identifier

0 references

1 reference

language of work or name

RITUXIMAB (English)

19 January 2016

1 reference

imported from Wikimedia project

English Wikipedia

0 references

electronic Essential Medicines List medicine ID

0 references

Encyclopedia of China (Third Edition) ID

subject named as

利妥昔单抗

0 references

1 reference

Freebase Data Dumps

publication date

28 October 2013

Microsoft Academic ID

0 references

0 references

1 reference

26 January 2022

https://docs.openalex.org/download-snapshot/snapshot-data-format

1 reference

UK Parliament thesaurus ID

subject named as

Rituximab

0 references

WikiProjectMed ID

0 references

WikiSkripta article ID

0 references

Sitelinks

Wikipedia(34 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(1 entry)

commonswiki Category:Rituximab

Retrieved from "https://www.wikidata.org/w/index.php?title=Q412323&oldid=2256003206"

NODES